Symbols

MREO

Mereo Biopharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MREO

Mereo Biopharma Group Plc

A clinical stage biopharmaceutical company focused on rare diseases and oncology

Industry

Pharmaceutical

Established Date

03/10/2015

Listing Date

04/24/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.mereobiopharma.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom

Business

Introduction

Mereo BioPharma Group plc was incorporated under the laws of England and Wales on 10 March 2015. The company is a biopharmaceutical company focused on the development of innovative therapies for rare diseases. It has established a portfolio of late-stage clinical candidates, including setrusumab for osteogenesis imperfecta and alvelestat for α-1 antitrypsin deficiency-related lung disease. The company's strategy involves the selective acquisition and development of rare disease product candidates that have progressed through prior research and development.

Company Financials

EPS

MREO has released its 2025 Q3 earnings. EPS was reported at -0.01, versus the expected 0.01, missing expectations. The chart below visualizes how MREO has performed over recent quarters, highlighting trends in earnings surprises.